Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ITRM

ITRM - Iterum Therapeutics plc Stock Price, Fair Value and News

$0.32-0.02 (-5.88%)
Market Closed

4/100

ITRM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

ITRM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.29

Target 3M

$0.32

Target 6M

$0.31

ITRM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ITRM Price Action

Last 30 days

10.3%

Last 90 days

-50.8%

Trailing 12 Months

-78.5%

ITRM RSI Chart

ITRM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ITRM Valuation

Market Cap

12.8M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

32.8

EV/EBITDA

-0.82

Price/Free Cashflow

-0.66

ITRM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.29

Target 3M

$0.32

Target 6M

$0.31

ITRM Fundamentals

ITRM Revenue

Revenue (TTM)

390.0K

ITRM Earnings

Earnings (TTM)

-27.0M

Earnings Growth (Yr)

-47.34%

Earnings Growth (Qtr)

-37.95%

ITRM Profitability

EBT Margin

-6842.31%

Return on Equity

365.28%

Return on Assets

-82.95%

Free Cashflow Yield

-152.66%

ITRM Investor Care

Shares Dilution (1Y)

130.37%

Diluted EPS (TTM)

-0.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202500390.0K0
2019715.0K530.0K276.0K37.0K
2018598.3K688.5K778.8K869.0K
2017000508.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Iterum Therapeutics plc

ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEiterumtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES14

Iterum Therapeutics plc Frequently Asked Questions

ITRM is the stock ticker symbol of Iterum Therapeutics plc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Iterum Therapeutics plc is 12.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ITRM's fair value in chart for subscribers.

The fair value guage provides a quick view whether ITRM is over valued or under valued. Whether Iterum Therapeutics plc is cheap or expensive depends on the assumptions which impact Iterum Therapeutics plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITRM.

As of Wed Jan 28 2026, ITRM's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 32.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITRM PE ratio will change depending on the future growth rate expectations of investors.